EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update

Alice P Chen iD, Christina L Rosenberger iD, Nancy Moore, Jared C Foster iD, Abdul Rafeh Naqash iD, Elad Sharon iD, Geraldine O'Sullivan Coyne iD, Gary K Schwartz iD, Richard F Riedel iD, John Glod, James S Hu, Anthony P Conley iD und 16 weitere

Journal of Clinical Oncology · 01.06.2026 · 44 (16) · 1490-1497

DOI: 10.1200/jco-25-02811 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.06.2026. Verfasst von Alice P Chen und 27 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Sarcoma, Alveolar Soft Part. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We previously reported initial results of the pivotal phase II trial of atezolizumab for patients with alveolar soft part sarcoma (ASPS; ClinicalTrials.gov identifier: NCT03141684 ). Here, we report on three additional years of observation. Fifty-three patients with ASPS received atezolizumab. Median duration of response increased to 37.0 months. Objective response rate (ORR) and median progression-free survival (mPFS) remained essentially as previously reported (35.8% [95% CI, 23.1 to 50.2] and 20.8 months [IQR, 7.6-not reached], respectively). ASPSCR1::TFE3 fusion type was determined for 47/53 patients; ORR and mPFS were higher among the 41 patients expressing type 1 (43.9% [95% CI, 28.5 to 60.2] and 28.3 months [IQR, 9.2-not reached], respectively) than the six patients expressing type 2 (0% [95% CI, 0 to 45.9] and 7.5 months [IQR, 3.9-not reached], respectively, PFS HR, 3.2 [95% CI, 1.01 to 10.2]). Eleven patients chose a per-protocol drug holiday (range, 3.5-26.4 months) after ≥2 years of treatment; two experienced disease progression during the holiday. Nine eligible patients elected to receive bevacizumab plus atezolizumab after progressing on monotherapy; ORR was 0% and mPFS was 18.5 months (IQR, 7.9-21.1) in this small cohort. Long-term results support using atezolizumab to treat ASPS, even for several years; a drug holiday with careful monitoring may be an option for some patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic AgentsSarcoma, Alveolar Soft PartAdultAgedFemaleHumansMaleMiddle AgedYoung AdultProgression-Free Survival

Substanzen

Antibodies, Monoclonal, HumanizedAntineoplastic Agentsatezolizumab

Autor:innen und Institutionen

  • Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.
  • Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH.
  • Duke Cancer Institute, Duke University Medical Center, Durham, NC.
  • Center for Cancer Research, National Cancer Institute, Bethesda, MD.
  • Division of Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA.
  • The University of Texas MD Anderson Cancer Center, Houston, TX.

ORCID-Profile: Alice P Chen, Christina L Rosenberger, Jared C Foster, Abdul Rafeh Naqash, Elad Sharon, Geraldine O'Sullivan Coyne, Gary K Schwartz, Richard F Riedel, Anthony P Conley, Melissa A Burgess, Elizabeth J Davis, Priscilla Merriam, Brian H Ladle, Scott H Okuno, James L Chen, Katherine V Ferry-Galow, Brandon L Miller, Deborah F Wilsker, Ralph E Parchment, James H Doroshow

Zitieren

APA

Chen, A. P., Rosenberger, C. L., Moore, N., Foster, J. C., Naqash, A. R., Sharon, E., O'Sullivan Coyne, G., Schwartz, G. K., Riedel, R. F., Glod, J., Hu, J. S., Conley, A. P., Read, W. L., Burgess, M. A., Davis, E. J., Merriam, P., Deshpande, H. A., Ladle, B. H., Okuno, S. H., …, & Doroshow, J. H. (2026). Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update. Journal of Clinical Oncology, 44(16), 1490-1497. https://doi.org/10.1200/jco-25-02811

Vancouver

Chen AP, Rosenberger CL, Moore N, Foster JC, Naqash AR, Sharon E, et al. Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update. Journal of Clinical Oncology. 2026;44(16):1490-1497. doi:10.1200/jco-25-02811

BibTeX
@article{Chen2026,
  author = {Chen, Alice P and Rosenberger, Christina L and Moore, Nancy and Foster, Jared C and Naqash, Abdul Rafeh and Sharon, Elad and O'Sullivan Coyne, Geraldine and Schwartz, Gary K and Riedel, Richard F and Glod, John and Hu, James S and Conley, Anthony P and Read, William L and Burgess, Melissa A and Davis, Elizabeth J and Merriam, Priscilla and Deshpande, Hari A and Ladle, Brian H and Okuno, Scott H and Beck, Jill C and Chen, James L and Ferry-Galow, Katherine V and Fino, Kristin K and Miller, Brandon L and Wilsker, Deborah F and Begum, Asma and Parchment, Ralph E and Doroshow, James H},
  title = {Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {16},
  pages = {1490--1497},
  doi = {10.1200/jco-25-02811}
}
Kostenlos starten →